Stocks · News reference
Major U.S. indices ended lower on Monday, with the Dow Jones Industrial Average falling 0.51% to 53,459.78
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
EyePoint Inc. (NASDAQ: EYPT) announced disappointing Phase 3 clinical trial results for DURAVYU on August 17, 2026, failing to meet its primary endpoint in the LUGANO trial for wet age-related macular degeneration treatment. The stock subsequently dropped over 66%, prompting a securities litigation investigation by KTMC on behalf of affected investors.
Wall Street analysts changed outlook on top companies. Check out complete rating changes, including upgrades/downgrades, on our page.
EyePoint, Inc. (EYPT) announced its participation in three major investor conferences in September 2026, including Citi Biopharma, Cantor Global Healthcare, and Morgan Stanley Global Healthcare conferences. The company will also present multiple scientific presentations at The Retina Society's 59th Annual Scientific Meeting, focusing on its lead product candidate DURAVYU (vorolanib intravitreal insert) for retinal diseases, including Phase 3 trial data for wet AMD treatment.
Nvidia CEO Jensen Huang's single use of the word 'visibility' during earnings signals the company's unprecedented insight into AI infrastructure demand across land, power, and supply chains. With top hyperscalers expected to spend $800 billion on capex in 2026 and $1.3 trillion in 2027, Nvidia's 70% revenue growth guidance and strategic equity stakes in networking and optical companies position it as the architect of AI factories rather than just a chip vendor, suggesting secular demand rather than a bubble.
NuScale Power is implementing specialized AI tools from Nuclearn and NPX to streamline its engineering, regulatory, and knowledge work for small modular reactor (SMR) development. The AI implementation reduced information search and verification time by up to 80%, addressing operational bottlenecks. However, the company remains in pre-commercial stages with only one secured project in Romania and is seeking a major deal with the Tennessee Valley Authority.